Chapter 5. Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models
- Dietmar W. Siemann3,4
Published Online: 31 MAY 2006
DOI: 10.1002/0470035439.ch5
Copyright © 2006 John Wiley & Sons, Ltd
Book Title

Vascular-Targeted Therapies in Oncology
Additional Information
How to Cite
Rojiani, M. V. and Rojiani, A. M. (2006) Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch5
Editor Information
- 3
Shands Cancer Center, University of Florida, Gainsville, Florida, USA
- 4
Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA
Publication History
- Published Online: 31 MAY 2006
- Published Print: 10 MAR 2006
ISBN Information
Print ISBN: 9780470012949
Online ISBN: 9780470035436
- Summary
- Chapter
Keywords:
- vascular-disrupting agents in preclinical models;
- effects of treatment;
- Vascular disrupting agents (VDA);
- targeting tumor vasculature;
- combretastatin and ZD6126;
- tumor supportive blood vessel attack;
- intratumoral vascular damage;
- human Kaposi's sarcoma (KSY-1) and renal cell carcinoma Caki-1 xenograft
Summary
This chapter contains sections titled:
Introduction
Animal models
Morphologic and morphometric analysis
Effects of treatment
Acknowledgments
References
